Wells Fargo Maintains Overweight on Insmed, Lowers Price Target to $160

Benzinga Newsdesk www.benzinga.com Negative 90.6%

Neg 90.6% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $177 to $160.